Rare Fatal Tumour in Children May Finally Be Treatable

 

The most malignant tumour in paediatrics has led to a discovery that identifies potential new targets for drug treatments. According to new findings, which were published in the journal Nature Genetics, there are several molecular alterations that drive the cancer, which is a rare, always fatal brain tumour in children.

 

Paediatric high-grade astrocytomas are extremely difficult to treat with radiation and surgery. Over the past 30 years, the tumours have resisted treatment attempts with an estimated 250 chemotherapy drugs and combinations. However, the new study, which came from scientists at Dana-Farber/Boston Children’s Cancer and Blood Disorders Centre and McGillUniversity, could help doctors choose targeted agents with a better chance of combating these paediatric high-grade astrocytomas. When sequencing tumour biopsy samples, the researchers identified a number of mutations or errors in the DNA code, as well as epigenetic changes, which alter how genes are expressed. Existing drugs may be able to block at least two of the new mutations, while other molecular targets provide new avenues to explore for creating future treatments.

 

The project began more than 10 years ago when clinicians came together to create a collaborative “precision medicine” clinical trial based at Dana-Farber/Boston Children’s. According to Mark Kieran, MD, PhD, a neuro-oncologist and clinical director of the Brain Tumour Centre at Dana-Farber/Boston Children’s, ‘For the most malignant tumour in paediatrics, we finally are beginning to gain a handle on the development of this disease, which is critical to devising effective therapies.’ Kiernan was a co-senior author of the paper alongside neuropathologist Keith Ligon, MD, PhD, of Dana-Farber/Boston Children’s, and two researchers from McGill.

 

The 10-year project has always been specifically aimed at making discoveries that would change the treatment for children with a type of high grade astrocytoma called diffuse intrinsic pontine glioma (DIPG). As DIPGs develop in the brainstem – the seat of crucial, basic body functions that keep people alive – they are impossible to remove safely with surgery and therefore are known as the most aggressive brain tumours in children. For the study – which doctors and patients from more than 20 institutions have now joined – the researchers take a biopsy from 100 children, analyse their tumour tissue using pathology and molecular testing, and plan treatment specifically for each patient based on the results. Kiernan notes, ‘Instead of treating all the patients the same, this trial obtains a biopsy at the time of diagnosis and the treatment is determined by the expression pattern of the tumour.’

 

Of the 40 tumour specimens underwent sequencing; 25 were from patients with DIPG tumours. Most of these were found to contain a mutation called K27M in the H3F3A protein that is a basic building block of the “epigenome.” While effective drugs for this mutation have not yet been found, the researchers of this study discovered that H3F3A mutations always occurred in conjunction with other mutations that could be targeted by existing drugs. One such new mutation has been identified before as the cause of a rare disorder, “stone man syndrome,” where the body’s tissues gradually turn to bone. This mutation – in the gene ACVR1 – has never been seen as involved in cancer before, but was found in five of the diffuse intrinsic pontine gliomas.

 

In the FGFR1 and PI3K cell growth signalling pathways, the researchers discovered additional mutations for which there are already drugs that can be used. These drugs – which are being tested in other cancers – work to block these overactive pathways. The study authors explain, ‘These alterations in growth factor receptors and in members of the PI3K pathway offer previously unforeseen therapeutic possibilities in a deadly cancer.’

Comments are closed.